Positron Emission Tomography in the Management of Lymphomas

Dietlein, 2000, Cost effectiveness of FDG PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results, Eur J Nucl Med, 27, 1598, 10.1007/s002590000376 Gould, 2001, Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis, JAMA, 285, 914, 10.1001/jama.285.7.914 Huebner, 2000, A meta-analysis of the literature for whole body FDG PET detection of recurrent colorectal cancer, J Nucl Med, 41, 1177 O'Doherty, 2000, Being equipped for clinical PET, Lancet, 356, 1701, 10.1016/S0140-6736(00)03200-1 Kostakoglu, 2000, Fluorine-18-fluorodeoxyglucosepositron emission tomography in the staging of and follow up of lymphoma: is it time to shift a gear, Eur J Nucl Med, 27, 1564, 10.1007/s002590000340 Mikhaeel, 2000, 18F-FDG-PET for the assessment of residual masses on CT after treatment of lymphomas, Ann Oncol, 11, S147, 10.1093/annonc/11.suppl_1.S147 de Wit, 1997, Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma, Ann Oncol, 8, 57, 10.1093/annonc/8.suppl_1.S57 Bangerter, 1999, Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest, Acta Oncologica, 38, 799, 10.1080/028418699432969 Bangerter, 1998, Whole body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) for accurate staging of Hodgkin's disease, Ann Oncol, 9, 1117, 10.1023/A:1008486928190 Bangerter, 1997, Usefulness of FDG-PET in diagnosing primary lymphoma of the liver, lnt J Hematol, 66, 517, 10.1016/S0925-5710(97)00068-6 Buchmann, 2001, 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial, Cancer, 91, 889, 10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5 Cremerius, 1998, Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma, Nucl Med Commun, 19, 1055, 10.1097/00006231-199811000-00005 de Wit, 2001, 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma, Ann Oncol., 12, 29, 10.1023/A:1008357126404 Hoh, 1997, Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma, J Nucl Med, 38, 343 Hueltenschmidt, 2001, Whole body positron emission tomography in the treatment of Hodgkin disease, Cancer, 91, 302, 10.1002/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4 Jerusalem, 1999, Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post treatment evaluation in Hodgkin's disease and non- Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging, Blood, 94, 429, 10.1182/blood.V94.2.429 Jerusalem, 1999, Whole-body l8F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma, Nucl Med Commun, 20, 13, 10.1097/00006231-199901000-00004 Jerusalem, 2000, Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma, Haematologica, 85, 613 Kotzerke, 1999, Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma, Eur J Nucl Med, 26, 31, 10.1007/s002590050356 Mainolfi, 1998, Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment, Radiol Med, 95, 98 Moog, 1997, Lymphoma. Role of whole-body 2-deoxy-2- [F-18]fluoro-D-glucose (FDG) PET in nodal staging, Radiology, 203, 795, 10.1148/radiology.203.3.9169707 Moog, 1998, Extranodal malignant lymphoma: detection with FDG PET versus CT, Radiology, 206, 475, 10.1148/radiology.206.2.9457202 Moog, 1998, 18-F- fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow, J Clin Oncol, 16, 603, 10.1200/JCO.1998.16.2.603 Moog, 1999, FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma, J Nucl Med, 40, 1407 Newman, 1994, Imaging of lymphoma with PET with 2-[F-18]-Fluoro-2-deoxy-D-glucose: Correlation with CT, Radiology, 190, 111, 10.1148/radiology.190.1.8259386 Partridge, 2000, Fluorodeoxyglucose Positron Emission Tomograpy and the Pretreatment Staging of Hodgkins Disease, Annals Oncol, 11, 1273, 10.1023/A:1008368330519 Stumpe, 1998, Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography, Eur J Nucl Med, 25, 721, 10.1007/s002590050275 Weidmann, 1999, Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease, Leukemia and Lymphoma, 34, 545, 10.3109/10428199909058482 Warburg, 1931 Kubota, 1992, Intratumoral distribution of fluorine-18-fluorodeoxyglucpse in vivo: high accumulation in macrophages and granulation tissue studied by microautoradiography, J Nucl Med, 33, 1972 Phekoo, KJ, Schey, SA, Bevan, D, Richards, S, Moller, H, Report of the South Thames Haematology register Sub committee on the incidence of Haematological malignancies in 1999 Segall, 2001, FDG PET imaging in patients with lymphoma: A clinical perspective, J Nucl Med, 42, 609 Mikhaeel, 2000, 18-FDG-PET as a Prognostic Indicator in the treatment of aggressive Non-Hodgkin's Lymphoma, Leukaemia and Lymphoma, 39, 543, 10.3109/10428190009113384 Romer, 1998, Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose, Blood, 91, 4464 Spaepen, 2001, Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?, J Clin Oncol, 19, 414, 10.1200/JCO.2001.19.2.414 O'Doherty, 2001, Clinical PET in the U.K.: dangers of missing an opportunity, Nucl Med Commun, 22, 737 Mijnhout, 2000, How to perform a comprehensive search for FDG-PET literature, Eur J Nucl Med, 27, 91, 10.1007/PL00006669 Jerusalem, 2001, Whole body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkins disease, Haematologica, 86, 266 Gupta, 2001, Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging, Chest, 120, 520, 10.1378/chest.120.2.521 Acland, 2001, Comparison of PET scanning and sentinel node biopsy in the detection of micrometastases of clinical stage I malignant melanoma, J Clin Oncol, 19, 2674, 10.1200/JCO.2001.19.10.2674 Leskinen-Kallio, 1991, Uptake of carbon-11 methionine and fluorodeoxyglucose in Non-Hodgkin's lymphoma: A PET study, J Nucl Med, 32, 1211 Hoffmann, 1999, Positron emission tomography with fluorine- 18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type, Ann Oncol, 10, 1185, 10.1023/A:1008312726163 Jerusalem, 2001, Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL), Ann Oncol, 12, 825, 10.1023/A:1011169332265 Carr, 1998, Detection of lymphoma in bone marrow by whole-body positron emission tomography, Blood, 91, 3340, 10.1182/blood.V91.9.3340 Becherer, 2002, Positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high dose chemotherapy with stem cell transplantation, Leukaemia, 16, 260, 10.1038/sj.leu.2402342 Torizuka, 2000, Metabolic response of Non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET, J Nucl Med, 41, 999 Naumann, 2001, Prognostic value of positron emission tomography in the evaluation of post treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma, Br J Haematol, 115, 793, 10.1046/j.1365-2141.2001.03147.x Schoder, 2001, Effect of whole-body 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma, J Nucl Med, 42, 1139 Zinzani, 1999, The role of positron emission tomography (PET) in the management of lymphoma patients, Ann Oncol, 10, 1181, 10.1023/A:1008327127033 Cai, 1999, CT and PET lung image registration and fusion in radiotherapy treatment planning using the chamfer-matching method, Int J Radiation Oncol Biol Phys, 43, 883, 10.1016/S0360-3016(98)00399-X Kiffer, 1998, The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer, Lung Cancer, 19, 167, 10.1016/S0169-5002(97)00086-X Nestle, 1999, 18F-deoxyglucose positron emission tomography (FDG PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis, Int J Radiation Oncol Biol Phys, 44, 593, 10.1016/S0360-3016(99)00061-9 Brink, 2001, Increased metabolic activity in the thymus gland studied with (18)F-FDG PET: Age dependency and frequency after chemotherapy, J Nucl Med, 42, 591 Higashi, 2000, Evaluation of the early effect of local irradiation on normal rodent bone marrow metabolism using FDG: preclinical PET studies, J Nucl Med, 41, 2026 Bakheet, 1998, Benign causes of 18-FDG uptake on whole body imaging, Semin Nucl Med, 28, 352, 10.1016/S0001-2998(98)80038-X Okada, 1991, The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis, J Nucl Med, 32, 686 Okada, 1994, FDG-PET for predicting the prognosis of malignant lymphoma, Ann Nucl Med, 8, 187, 10.1007/BF03164996 Weihrauch, 2001, Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkins disease, Blood, 98, 2930, 10.1182/blood.V98.10.2930 Walsh, 1996, The use of PET-18 FDG imaging in the evaluation of head and neck lymphoma, Clin Oncol (R Coll Radiol), 8, 151, 10.1016/S0936-6555(05)80040-8 Weinblatt, 1997, False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease, J Nucl Med, 38, 888 Cook, 1998, Normal physiology and benign pathological variants in 18FDG PET scanning: potential for error in interpretation, Semin Nucl Med, 26, 308, 10.1016/S0001-2998(96)80006-7 Sugawara, 1998, Preclinical and clinical studies of bone marrow uptake of fluorine-l8-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy, J Clin Oncol, 16, 173, 10.1200/JCO.1998.16.1.173 Sugawara, 1999, Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results, J Nucl Med, 40, 1456 Weber, 1999, Reproducibility of metabolic measurements in malignant tumours using FDG PET, J Nucl Med, 40, 1771 Lapela, 1995, Increased glucose metabolism in untreated Non-Hodgkin's lymphoma: A study with positron emission tomograpgy and fluorine-18-deoxyglucose, Blood, 86, 3522, 10.1182/blood.V86.9.3522.bloodjournal8693522 Rodriguez, 1995, Predicting malignancy grade with PET in None-Hodgkin's lymphoma, J Nucl Med, 36, 1790 Nuutinen, 1998, Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas, Eur J Nucl Med, 25, 729, 10.1007/s002590050276 Martiat, 1988, In vivo measurement of carbon-11 thymidine uptake in non-hodgkins lymphoma using positron emission tomography, J Nucl Med, 29, 1633 Klose, 2000, Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography, Eur J Nucl Med., 27, 1457, 10.1007/s002590000323 Tolley, 1998 Valk, 2000, Randomized controlled trials are not appropriate for imaging technology evaluation, J Nucl Med, 41, 1125